Chronic central serous chorioretinopathy (CSCR). Central serous chorioretinopathy, unspecified eye
Conditions
Interventions
Intervention group: A single dose intravitreal injection of 50 mg propranolol hydrochloride in a 0.05 ml solution.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Chronic CSCR (at least for 4 months) Willingness to participate in the study and complete the informed ethical consent form
Exclusion criteria
Exclusion criteria: History of retinal MPC, PRP, or PDT History of any intravitreal Anti-VEGF injection History of any ocular surgery except an uneventful cataract surgery more than 6 months ago Presence of any other ocular conditions such as uveitis, glaucoma, hypertensive retinopathy, KCN, diabetic retinopathy, or CNV Clinically significant cataract needing a surgical intervention Use of any immunomodulating medications such as corticosteroids Use of any supplementary anti-oxidants such as vitamin E Use of any systemic medication with known effect on macula such as Fingolimod or Deferoxamine Receiving chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central macular thickness. Timepoint: Central macular thickness evaluation before intravitreal injection and 1 month after injection. Method of measurement: Macular OCT imaging.;Visual acuity. Timepoint: Visual acuity evaluation before intravitreal injection, and one week and four weeks after injection. Method of measurement: evaluation with an E-chart in 6 meters distance.;Ophthalmic and systemic side effects. Timepoint: 1 day, 1 week, and 4 weeks after intravitreal injection. Method of measurement: Ophthalmic examination with slit lamp and medical questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Amiri
Tabriz University of Medical Sciences
Outcome results
None listed